

PATENT ASSIGNMENT

Electronic Version v08
Stylesheet Version v02

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT OF ASSIGNOR'S INTEREST

CONVEYING PARTY DATA

Name	Execution Date
Thomas SMITH	2006-03-20

RECEIVING PARTY DATA

Name	Street Address	Internal Address	City	State/Country	Postal Code
St. James Associates LLC/Faber Research Series	240 Taos Road		Altadena	CA	91001

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number	10538589

CORRESPONDENCE DATA

FAX NUMBER: (617) 526-5000

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

When the customer number has been provided, the Office of Public Records will obtain the correspondence data from the official record on file at the USPTO.

CUSTOMER NUMBER: 23483

NAME OF PERSON SIGNING:

Michael J. Twomey

DATE SIGNED:

2006-05-15

Total Attachments: 6

source=011298100125US36-usassn-A000001.tif
source=011298100125US36-usassn-A000002.tif
source=011298100125US36-usassn-A000003.tif
source=011298100125US36-usassn-A000004.tif
source=011298100125US36-usassn-A000005.tif
source=011298100125US36-usassn-A000006.tif

CH \$40.00 080219 10538589

PATENT

800025738

REEL: 017615 FRAME: 0344

ASSIGNMENT

WHEREAS, I, **Thomas J. Smith**, a citizen of Canada and residing at 240 Taos Road, Altadena, California 91001, USA; am the inventor of certain new and useful inventions and discoveries which are disclosed in the following patent applications:

Application No.	Filing Date	Country	Title
60/435,163	20 December 2002	US	Large crystalline formulations for sustained release delivery of alkylating agents
60/435,416	20 December 2002	US	Large crystalline formulations for sustained release delivery of aminoglycosides
60/435,445	20 December 2002	US	Large crystalline formulations for sustained release delivery of angiotensin II receptor antagonists
60/435,415	20 December 2002	US	Large crystalline formulations for sustained release delivery of antibiotics for the prophylaxis or treatment of anthrax
60/435,448	20 December 2002	US	Large crystalline formulations for sustained release delivery of anti-Parkinson agents
60/435,449	20 December 2002	US	Large crystalline formulations for sustained release delivery of anti-biotics
60/435,447	20 December 2002	US	Large crystalline formulations for sustained release delivery of antidepressants
60/435,506	20 December 2002	US	Large crystalline formulations for sustained release delivery of antiepileptics
60/435,505	20 December 2002	US	Large crystalline formulations for sustained release delivery of antimetabolites
60/435,507	20 December 2002	US	Large crystalline formulations for sustained release delivery of atypical antipsychotics
60/435,496	20 December 2002	US	Large crystalline formulations for sustained release delivery of beta blockers

Application No.	Filing Date	Country	Title
60/435,075	20 December 2002	US	Large crystalline formulations for sustained release delivery of calcium channel blockers
60/435,423	20 December 2002	US	Large crystalline formulations for sustained release delivery of camptothecins
60/435,336	20 December 2002	US	Large crystalline formulations for sustained release delivery of cephalosporin antibiotics
60/435,630	20 December 2002	US	Large crystalline formulations for sustained release delivery of corticosteroids
60/435,372	20 December 2002	US	Large crystalline formulations for sustained release delivery of epidophylotoxins
60/435,106	20 December 2002	US	Large crystalline formulations for sustained release delivery of fluoroquinolones
60/435,388	20 December 2002	US	Large crystalline formulations for sustained release delivery of HMG Co-A reductase inhibitors
60/435,632	20 December 2002	US	Large crystalline formulations for sustained release delivery of immunosuppressive agents
60/435,557	20 December 2002	US	Large crystalline formulations for sustained release delivery of local anesthetics
60/435,558	20 December 2002	US	Large crystalline formulations for sustained release delivery of macrolide antibiotics
60/435,132	20 December 2002	US	Large crystalline formulations for sustained release delivery of methadone
60/435,497	20 December 2002	US	Large crystalline formulations for sustained release delivery of non-nucleoside reverse transcriptase inhibitors
60/435,494	20 December 2002	US	Large crystalline formulations for sustained release delivery of opiates

Application No.	Filing Date	Country	Title
60/435,508	20 December 2002	US	Large crystalline formulations for sustained release delivery of penicillin antibiotics
60/435,501	20 December 2002	US	Large crystalline formulations for sustained release delivery of HIV protease inhibitors
60/435,565	20 December 2002	US	Large crystalline formulations for sustained release delivery of platinum coordination complexes
60/435,038	20 December 2002	US	Large crystalline formulations for sustained release delivery of nucleoside reverse transcriptase inhibitors
60/435,037	20 December 2002	US	Large crystalline formulations for sustained release delivery of taxanes
60/435,162	20 December 2002	US	Large crystalline formulations for sustained release delivery of tetracycline antibiotics
60/435,338	20 December 2002	US	Large crystalline formulations for sustained release delivery of anti-tuberculosis agents
60/435,509	20 December 2002	US	Large crystalline formulations for sustained release delivery of vinca alkaloids
60/435,495	20 December 2002	US	Large crystalline formulations for sustained release delivery of angiotensin converting enzyme inhibitors
60/450,722	28 February 2003	US	Large crystalline formulations for sustained release delivery of estrogen receptor modulators
60/454,997	14 March 2003	US	Large crystalline formulations for sustained release delivery of isoflavones
10/538,589	15 June 2005	US	Coated particles for sustained-release pharmaceutical administration
2003299982	22 December 2003	AU	Coated particles for sustained-release pharmaceutical administration

Application No.	Filing Date	Country	Title
2510320	22 December 2003	CA	Coated particles for sustained-release pharmaceutical administration
03800247.3	22 December 2003	EP	Coated particles for sustained-release pharmaceutical administration
2005-510069	22 December 2003	JP	Coated particles for sustained-release pharmaceutical administration
US2003/41391	22 December 2003	PCT	Coated particles for sustained-release pharmaceutical administration

WHEREAS, **St. James Associates LLC/Faber Research Series**, whose address is 240 Taos Road, Altadena, California 91001, USA, which, together with its successors and assigns is hereinafter called "ASSIGNEE," is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited;

NOW, THEREFORE, for and in consideration of my employment by ASSIGNEE and other valuable consideration furnished by ASSIGNEE to me, receipt and sufficiency of which I hereby acknowledge, I hereby, without reservations:


1. Assign, transfer, and convey to ASSIGNEE the entire right, title, and interest in and to said inventions and discoveries, said United States Patent Applications, any and all other applications for Letters Patent(s) on said inventions and discoveries in whatsoever countries, including all divisional, renewal, substitute, continuation, continuation-in-part, reexamination and convention applications based in whole, or in part, upon said inventions or discoveries, or upon said United States Patent Applications, and any and all Letters Patent(s), reissues, and extensions of Letters Patent(s) granted for said inventions and discoveries or upon said applications, and every priority right that is or may be predicated upon, or arise from, said inventions, said discoveries, said applications, and said Letters

Patent(s);

2. Authorize ASSIGNEE to file patent applications in any or all countries on any or all of said inventions and discoveries in our names or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable, under International Conventions or otherwise;
3. Authorize and request the Commissioner of Patents and Trademarks of the United States of America and the empowered officials of all other governments throughout the world to issue or transfer all said Letters Patent(s) to ASSIGNEE, as assignee of the entire right, title, and interest therein or otherwise as ASSIGNEE may direct;
4. Warrant that I have not knowingly conveyed to others any right in said inventions, discoveries, applications, or patents, or any license to use the same, or to make, use, or sell anything embodying or utilizing any of said inventions or discoveries; and that I have good right to assign the same to ASSIGNEE without encumbrance;
5. Bind my heirs, legal representatives, and assigns, as well as myself, to do, upon ASSIGNEE's request and at ASSIGNEE's expense, but without additional consideration to either myself or them, all acts reasonably serving to assure that said inventions and discoveries, said patent applications, and said Letters Patent(s) shall be held and enjoyed by ASSIGNEE as fully and entirely as the same could have been held and enjoyed by myself, my heirs, legal representatives, and assigns if this Assignment had not been made; and particularly to execute and deliver to ASSIGNEE all lawful application documents including petitions, specifications, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by ASSIGNEE; and to communicate to ASSIGNEE all facts known to me relating to said inventions and discoveries or the history thereof, and to testify as to the same in any court or proceeding; and to furnish ASSIGNEE any and all documents, photographs, models, samples, and other physical exhibits in my control or in the control of my heirs, legal

representatives, or assigns which may be useful for establishing the facts of our conceptions, disclosures, and reduction to practice of said inventions and discoveries.


Signed at ALTADENA this 20th day of MARCH, 2006.



Signature of **Thomas J. Smith**

Witness Statement

I, Ellen Doble-Smith Steel, whose full post office address is 240 Taos Road
Altadena CA 91001,
state that I was personally present and did see **Thomas J. Smith**, who is personally known to me to be the person named in the above assignment, duly sign and execute the same on the date set forth above.



(Signature of Witness)